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TECHNICAL NOTE
Measurement of GFR with a single intravenous injection of
nonradioactive iothalamate
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Rigorous assessment of the glomerular filtration rate (GFR)
requires the measurement of the renal clearance of inulin, a
fructose polymer that fulfills the criteria for an ideal filtration
marker [1, 2]. However, the classical inulin clearance method is
not suitable for routine clinical purposes, since it requires
continuous intravenous infusion and, sometimes, bladder cath-
eterization of the patients [3]. Simultaneous studies of renal
inulin clearance and plasma 51Cr-EDTA clearance have dem-
onstrated that the plasma clearance of 51Cr-EDTA is a reliable
index of GFR [4, 5], with the advantage that it avoids the need
for urine collection and continuous intravenous infusion of the
tracer. This simple and reliable technique is now commonly
used in clinical practice, but still maintains the drawbacks
associated with the use of radiolabeled compounds, such as the
need for special licensing, compliance with complicated proce-
dures for handling, storage and disposal of contaminated
wastes, and the exclusion of certain patients, such as pregnant
women, from the examination. The development of simple
methods for the determination of iothalamate [6—9] and of other
x-ray tracers [10—13] allows the use of unlabeled compounds for
the measurement of GFR. Again, the need for urine collection
and continuous intravenous infusion [9, 11, 14] or subcutaneous
injection mixed with epinephrine [15] in order to maintain
constant plasma concentration of the tracer, make this tech-
nique impractical for routine clinical use. In the present study
we describe a rapid, simple and reliable method for the evalu-
ation of renal function by the measurement of plasma clearance
of unlabeled iothalamate. We also validate the method by
comparing the plasma and the renal clearances of iothalamate
with the plasma clearance of 51Cr-EDTA in kidney patients with
different degrees of renal function.
Methods
Simultaneous clearance studies were performed with iothala-
mate and 51Cr-EDTA in 19 patients (13 men and 6 women) who
gave informed consent according to the Declaration of Helsinki
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(Table 1). All the patients received a 3 g intravenous dose of
unlabeled iothalamate (Conray® 60, Bracco, Milan, Italy) to-
gether with 1 MCi/kg of 51Cr-EDTA (Amersham International,
Buckingamshire, UK). Immediately before the injection and 5,
10, 20, 30, 40, 50, 60, 90, 120, 180, 240, 300, 450, and 600
minutes thereafter, 2 ml of blood were collected from an
antecubital vein through a 19-gauge needle, and, following
centrifugation at room temperature (2000 x g for 20 mm),
plasma was separated and stored at —20°C for the HPLC
determination of iothalamate concentration. Additional 6 ml of
blood were collected at each sampling point and stored at 4°C
for 51Cr-EDTA analysis. Diuresis was established with oral
water loading. Furosemide was infused only in the two edem-
atous patients (no. 13 and 15, Table 1). The patients were asked
to void 60 minutes after the injection of iothalamate and
51Cr-EDTA; urines were then collected by spontaneous voiding
at 120, 180, 300 and 600 minutes after the injection for measure-
ment of iothalamate excretion.
Plasma and urinary concentrations of iothalamate were de-
termined by HPLC as reported in detail elsewhere [16], Briefly,
a 500-pd volume plasma, acidified with I N HC1 (1 ml), was
extracted with ethyl acetate. After centrifugation the organic
layer was separated and evaporated to dryness. The residue
was redissolved in 400 pi of eluent and 20 d of the aqueous
phase was injected into the liquid chromatograph. Urine sam-
ples were centrifuged and diluted 1: 10 with distilled water, then
1 ml of diluted sample was treated as described for plasma.
Samples were chromatographed on a strong anion-exchange
high-performance column in isocratic conditions. Internal cali-
bration curves of iothalamate were prepared for each set of
samples. Linearity was found over the investigated concentra-
tion range. The detection limit was 0.5 g/ml. 51Cr-EDTA
concentration was determined by radioactivity counting in a
gamma counter.
Plasma clearances of iothalamate and 51Cr-EDTA were cal-
culated by the formula: Cl = Dose/AUC, where AUC is the
area under the plasma concentrations. lothalamate and 51Cr-
EDTA plasma profiles were analyzed by a two-compartment
open model system. All data were fitted by a non-linear
regression iterative program (Carl Peck, Uniformed Services
University, Bethesda, Maryland, USA) and flooded according
to Sacchi-Landriani, Guardabasso and Rocchetti [17] on an
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Table 1. Clinical characteristics of patients at study entry
Patient
no.
Age
years
Sex Body
weight
kg
Body surface
area
m2
Serum
creatinine
mgldl
Creatinine
clearance
ml/min/1.73 m2 Diagnosis
1 28 M 77 1.93 1.3 105.68 IgA nephropathy
2 67 F 100 2.11 3.9 18.85 Diabetic nephropathy
3 18 M 125 2.49 1.2 90.22 Unilateral kidney
4 64 F 61 1.57 5.0 17.00 Polycystic kidney
5 32 M 74 1.90 1.0 55.56 Diabetic nephropathy
6 68 F 48 1.51 1,7 16.00 Vasculitis
7 51 M 57 1.63 3.7 24.30 Diabetic nephropathy
8 44 F 96 1.98 5.2 11.30 Nephropathy of uncertain origin
9 59 M 76 1.89 2.1 61.69 IgA nephropathy
10 56 F 53 1.55 3.0 16.74 Membranoproliferative glomerulonephritis
11 54 M 73 1.82 3.8 17.00 Diabetic nephropathy
12 38 M 82 1.94 2.2 60.00 IgA nephropathy
13 51 M 77 1.88 5.9 13.00 Focal glomerulosclerosis
14 56 F 62 1.60 8.9 5.00 Polycystic kidney
15 26 M 63 1.75 10.0 7.00 Membranoproliferative glomerulonephritis
16 69 M 75 1.90 6.1 13.00 Chronic glomerulonephritis
17 50 M 73 2.02 6.7 12.00 Membranoproliferative glomerulonephritis
18 31 M 63 1.73 0.9 177.67 Essential hypertension
19 33 M 103 2.36 1.1 130.91 Diabetes mellitus
HP-86 computer (Hewlett-Packard). The clearances of iothala-
mate and 51Cr-EDTA were also estimated by using the mea-
surements from the timed period 120 to 600 minutes after the
injection, according to a one-compartment model (Cl1) by the
formula: Cl1 DoseIC0IA), where the elimination rate constant
A and the intercept on the ordinate, C0, were calculated from
the least squares semi-log curve fit. According to Bröchner-
Mortensen [18], plasma clearances were then estimated by the
formula: Cl (0.990778 x Cl1) — (0.001218 x Cl12).
lothalamate renal clearances were calculated in the timed
period 120 to 600 minutes after injection from the formula: (U x
VIP) x (1.73IBSA), where: U = urine concentration of iothala-
mate, V = volume of urine per minute, P = plasma concentra-
function
5'Cr-EDTA clearance
mI/mm/i .73 m2
lothalamate clearance
mI/mini] .73 m2
Patient
no.
Plasma Plasma Renal
B,-M.
Fittinga formula"
B.-M.
Fitting formula
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
74.75 73.82
11.54 11.09
77.73 71.46
11.65 11.36
153.33 147.85
26.13 24.68
24.10 21.87
12.59 11.62
37.16 35.61
21.45 18.88
17.02 16.45
56.32 53.94
12.11 12.04
5.72 7.06
8,27 8.43
13.26 12.38
11.87 9.13
147.58 127.46
80.81 78.84
78.50 79.75
16.74 16.37
63.44 63.54
11.26 13.51
157.47 149.41
26.76 28.92
23.86 23.66
13.29 13.43
34.35 33.78
22.03 21.56
16.41 16.76
48.28 47.74
12.98 13.08
9.04 10.00
7.68 8.52
14.96 13.87
9.22 7.37
150.83 138.37
85.83 90.97
76.02
12.32
68.04
10.88
159.79
34.46
23.21
9.97
45.37
11.27
11.27
49.18
11.60
5.14
6.93
9.28
9.52
151.89
90.41
tion of iothalamate at the midpoint of each clearance period,
and BSA body surface area. Results were analyzed by
Student's t-test and linear regression analysis, as appropriate. P
values less than 0.05 were considered significant.
Results
Standard curves were constructed using human plasma and
urine spiked with known amounts of iothalamate. Linearity was
Table 2. Clearance studies in subjects with different degrees of renal500
200
E—
100
0-c-.
50
cD' 20
00
—C.) 10
5
Time, minutes
Fig. 1. lothalamate plasma profile following intravenous injection in
three representative patients with different degrees of renal function.
Symbols are: (U) patient #1, clearance: 78.50 ml/min/1.73 m2; (LI)
patient #9, clearance: 34.35 mlimin/ 1.73 m2; (•) patient #15, clearance:
7.68 ml/minil.73 m2.
0 60 120 180 240 300 360420480 540 6ciO
a Calculated by fitting plasma concentrations by a two-compartment
open modelb Calculated by the BrOchner-Mortensen formula as described in the
text
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Fig. 3. Correlation between iothalamate plasma and renal clearance.
found over the investigated range for iothalamate (from 0.5 to
500 g/ml for plasma, and from 0.5 to 10 mg/mi for urine) and
calibration curves had correlation coefficients better than 0.998.
The plasma iothalamate concentrations were best described
by a two-compartment pharmacokinetic open model, and the
profile was linear (elimination phase) at least from 120 minutes
after injection in all the studied patients. Figure 1 shows the
plasma curves of iothalamate following a single intravenous
injection in three patients with different degrees of renal func-
tion.
Plasma clearances of iothalamate and 51Cr-EDTA calculated
by the two-compartment open model system were almost
identical (Table 2), and a good correlation was found between
the plasma clearances of the two compounds (Fig. 2A). Similar
values were obtained by using the one-compartment model
corrected according to the method of Brochner-Mortensen
(Table 2, Fig. 2B). Plasma clearances of iothalamate were also
similar to the renal clearances of the compound and a good
correlation was found between the two clearance methods (Fig.
3).
Fig. 2. Correlation between 51Cr-EDTA and
iothalamate clearances. A. Clearances
calculated by the two-compartment open
model system. B. Clearances calculated by
the one-compartment open model system and
then corrected by means of the Brochner-
Mortensen equation.
The above regression estimates were also performed after log
transformation of the clearance values. The standard error of
the slope estimates established that 95% confidence intervals
for each slope included 1.0 (that is, the line of identity). Thus
the models cannot be rejected by the data at a significance level
of 0.05.
Discussion
The present data indicate a highly significant correlation
between the plasma clearance of unlabeled iothalamate and that
of 51Cr-EDTA [19, 20] as measured by a two-compartment
model over a wide range of GFRs.
Measuring GFR by plasma clearance techniques has the
advantage of avoiding the need for urine collection and contin-
uous infusion of the marker of glomerular filtration. However,
the use of a two-compartment model requiring frequent and
numerous plasma collections makes the method cumbersome.
The findings that plasma profiles of iothalamate and 51Cr-
EDTA were identical suggest that the two compounds are
handled in humans in almost the same manner. Thus, we
analyzed the applicability to iothalamate of a simplified method
for the measurement of GFR already described for 51Cr-EDTA
[18] which utilizes a one-compartment model. The clearance
was calculated from the slope of the terminal plasma curves (the
drawing of which demands only few blood samples) according
to a one-compartment open model, and then the clearance
values were corrected with the Bröchner-Mortensen formula
[18]. The finding of an excellent correlation (slope statistically
not different from 1) between the one-compartment model
corrected with the Bröchner-Mortensen formula and the two-
compartment model, confirms the reliability of this simplified
technique.
The estimation of GFR by plasma clearance techniques relies
on the assumptions that extrarenal clearance of the tracer is
negligible. Thus, the reliability of the technique might be
reduced in patients with severe renal insufficiency. This possi-
bility has been extensively discussed for 51Cr-EDTA [211 with
conflicting conclusions. We addressed this problem in our
patients (7 of which had a GFR < 15 ml/min/l.73 m2) by
comparing plasma clearance of iothalamate with the renal
clearance of the compound. The findings of a highly significant
correlation between plasma and renal clearances of iothalamate
and of a scattered distribution of the results around the line of
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identity, strongly suggest that extrarenal routes of excretion of
the tracer are negligible and that plasma clearance of iothala-
mate can also be applied to the measure of GFR in patients with
severe renal insufficiency. Therefore, in such patients blood
sampling over a long period allows the possible limits of the
single injection clearance method when clearance is low relative
to body size to be overcome. Furthermore, the proposed
technique offers the advantage of avoiding the possible effects
on GFR of furosemide infusion, which is required during renal
clearance study for adequate urine collection in patients with
severe renal failure and fluid retention [22]. However, one
should consider that this method as well the others based on the
single injection of the tracer is of little value when acute
changes of GFR are to be measured.
In conclusion, the proposed method of measuring GFR by the
plasma clearance of unlabeled iothalamate is a good alternative
to the methods currently in use and may be particularly suitable
in clinical practice and for follow-up studies requiring repeated
measurements of GFR. Actually, the measurement of iothala-
mate by the HPLC method is easy to reproduce, quick and
reliable [16]. Moreover, the use of a one-compartment model
reduces the number of blood samples and further simplifies the
procedure.
Reprint requests to Giuseppe Remuzzi, M.D., Mario Negri Institute
for Pharmacological Research, Via Gavazzeni, 11, 24100 Bergamo,
Italy.
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